{"disease":{"id":"facial-angiofibroma","name":"facial angiofibroma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03826628","title":"Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":107,"lead_sponsor_name":"Dermatology Specialties Limited Partnership","has_results":true},{"nct_id":"NCT03140449","title":"Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT02654340","title":"Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)","phase":"","overall_status":"TERMINATED","enrollment_count":20,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}